Search results for: Adrian Towse
Filter search results
OHE Response to Public Consultation on NICE Principles
7 February 2019
…pp.145-165. DOI. RePEc. Shah, K.K., 2017. Valuing Health at the End of Life. PhD thesis. Sheffield: University of Sheffield. Towse, A. and Garau, M., 2018. Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY…
The World Needs Better Drugs for TB. The Center for Global Development and OHE Have a Proposal and We Need your Feedback
5 March 2019
…Development. This blog post has also been published on the Center for Global Development website. Chalkidou, K., Garau, M., Nemzoff,C., Rodes-Sanchez, M., Silverman, R., and Towse A. (2019). Blueprint for…
The Economics of Innovation in Times of Pandemic: How to Incentivise the Development, Supply, and Continuous Improvement of Innovative Solutions to Fight COVID-19?
22 May 2020
…to develop better technologies that deliver more health and economic gain. Chalkidou, K., Towse, A., Silverman, R., Garau, M., & Ramakrishnan, G. (2020). Market-driven, value-based, advance commitment (MVAC): accelerating the…
The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis
30 June 2022
…value of a novel orphan medicine. Related research Towse, A. and Garau, M. (2018). Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence. OHE Consulting Report. RePEc Garau,…
Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
1 April 2012
…of co-dependent technologies. A revised version of this paper has been published in Personalized Medicine and can be downloaded from: http://www.futuremedicine.com/doi/abs/10.2217/pme.12.99 Please cite as: Garau, M., Towse, A., Garrison, L.,…
Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches
1 August 2011
…has been published in PharmacoEconomics and can be downloaded from: http://link.springer.com/article/10.1007%2Fs40273-012-0001-x Please cite as: Sussex, J., Towse, A. and Devlin, N., 2013. Operationalizing value-based pricing of medicines. PharmacoEconomics, 31(1), pp.1-10….
Incentives for R&D for New Antimicrobial Drugs
1 April 2011
…and can be downloaded from: http://www.tandfonline.com/doi/abs/10.1080/13571516.2011.584434 Please cite as: Towse, A. and Sharma, P., 2011. Incentives for R&D for new antimicrobial drugs. International Journal of the Economics of Business, 18(2),…
Using QALYs in Cancer: Review of the Methodological Limitations
1 October 2010
…and can be downloaded from: http://link.springer.com/article/10.2165%2F11588250-000000000-00000 Please cite as: Garau, M., Shah, K.K., Mason, A.R., Wang, Q., Towse, A. and Drummond, M.F., 2011. Using QALYs in cancer. Pharmacoeconomics, 29(8), pp.673-685….
Industrial Policy and the Pharmaceutical Industry
1 January 1995
…dealing with the European Community, Japan and the US are by Yarrow, and Professors Neary and Scherer, respectively. In the fourth paper Hale and Towse assess how valuable the UK-based…